Basic Fibroblast Growth Factor Mediates Carotid Plaque Instability Through Metalloproteinase-2 and -9 Expression  by Sapienza, P et al.
Basic Fibroblast Growth Factor Mediates Carotid Plaque
Instability Through Metalloproteinase-2 and -9 Expression
P. Sapienza,* L. di Marzo, V. Borrelli, A. V. Sterpetti, A. Mingoli,
R. Piagnerelli and A. Cavallaro
Department of Surgery ‘Pietro Valdoni’, University of Rome ‘La Sapienza’, Rome, Italy
Objective(s). We hypothesized that basic fibroblast growth factor (bFGF) may exert a role in carotid plaque instability by
regulating the expression of matrix metalloproteinases (MMP).
Methods. Plaques obtained from 40 consecutive patients undergoing carotid endarterectomy were preoperatively classified
as soft or hard. Serum bFGF was pre- and postoperatively measured. The release of MMP-2 and MMP-9 in the blood serum,
and the activity, production and expression in the carotid specimens was analyzed. Specific anti-bFGF inhibition tests were
performed in vitro on human umbilical artery smooth muscle cells (HUASMC) to evaluate the role of bFGF in the activity,
production and expression of MMP-2 and -9.
Results. Twenty-one (53%) patients had a soft carotid plaque and 19 (48%) a hard plaque. Preoperative bFGF serum levels
were higher in patients with soft plaques [soft ¼ 34 (28–39) pg/mL and hard ¼ 20 (17–22) pg/mL—p , 0.001] and
postoperatively returned to normal values (when compared to 10 healthy volunteers). The serum levels of MMP-2 in
patients’ with soft plaques were higher than those in patients’ with hard plaques [soft ¼ 1222 (1190–1252) ng/mL and
hard ¼ 748 (656–793) ng/mL—p , 0.0001]. MMP-9 serum values were 26 (22–29) ng/mL for soft plaques and 18 (15–
21) ng/mL for hard plaques (p , 0.0001). We found increased activity, production and expression of MMP-2 and -9 in soft
plaques compared to hard plaques (p , 0.001). In vitro inhibition tests on HUASMC showed the direct influence of bFGF
on the activity, production and expression of MMP-2 and -9 (p , 0.001).
Conclusions. bFGF seems to exert a key role in carotid plaque instability regulating the activity, production and expression
of MMP thus altering the physiologic homeostasis of the carotid plaque.
Key Words: bFGF; Metalloproteinases; Carotid endarterectomy; Atherosclerosis; Unstable carotid plaques; Stable carotid
plaques.
Introduction
Atherosclerosis leads to myocardial infarction and
stroke and is the principal cause of death in Western
countries.1 Advanced atherosclerotic plaques are
characterized by a lipid core covered by a fibrous
cap composed of smooth muscle cells (SMC) and
extracellular matrix. Lesions with a thin fibrous cap
overlying a large lipid-rich core are more vulnerable to
plaque rupture.2 The fibrous cap is composed of
extracellular matrix that includes collagens, elastins
and proteoglycans.3 A number of proteolytic enzymes,
particularly matrix metalloproteinases (MMP), are
present in atherosclerotic plaques.4 Degradation of
extracellular matrix by MMP, causing intraplaque
hemorrhage, cap rupture, and cap ulceration, may
promote plaque instability and prelude to the onset of
cerebral ischemic events.2,4 Recent studies suggest that
MMP are important in atherosclerosis development
and complications. These enzymes are the physio-
logical regulators of the extracellular matrix5 and are
secreted as proenzymes requiring extracellular acti-
vation after which they are capable of degrading
virtually all components of the extracellular matrix.6
MMP-2 (72 kDa gelatinase/type IV collagenase,
gelatinase A) cleaves a number of substrates including
gelatins, collagen types IV, V, VII, X and XI, fibronectin,
elastin and proteoglycan. MMP-2 has been identified
in a number of tissues, cells and plasma/serum and it
is secreted as a precursor form.7,8 MMP-9 (92 kDa
gelatinase/type IV collagenase, gelatinase B) has a
broad range of substrate specificity for native col-
lagens including types I, III, IVand Vas well as gelatin,
proteoglycans and elastin, it is secreted as a precursor
form.9 Since MMP-2 and -9 efficiently degrade type IV
collagen, the major structural component of basement
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membrane, they may have a predominant role in
carotid plaque instability.
Cytokines and growth factors secreted by SMC,
endothelial cells (EC) and macrophages might also
induce the release of matrix-degrading proteases.
Basic fibroblast growth factor (bFGF), a growth factor
member of the heparin-binding growth factors,10
ubiquitously distributed and with mitogenic activity
both for EC and SMC,11 may theoretically have a role
in extracellular matrix remodelling regulating the
expression of MMP.
We investigated the role of bFGF in plaque
instability, in particular whether it regulated the
expression of MMP.
Materials and Methods
Forty consecutive patients (26 men and 14 women;
mean age 71 ^ 7 years; median 72 years; range min.
60-max. 87 years) presenting at our institution with
internal carotid artery stenosis greater than 70% were
entered into this study after informed consent was
obtained. All patients were studied preoperatively
with color Doppler, magnetic resonance angiography
to confirm the degree of stenosis and cerebral
magnetic resonance.
The carotid plaque was echographically (Acuson
128 XP/4, Computed Sonography, USA) characterized
as uniformly anechogenic, predominantly hypoecho-
genic, predominantly echogenic, uniformly echogenic.
The luminal surface of the plaque was also defined as
regular, irregular (with recess between 0.4 and 2 mm
in depth and width) and irregular (with recess more
than 2 mm in depth and width). The presence of dis-
ruption or marked irregularities of the plaque surface,
on two-dimensional cross-sectional and longitudinal
views of carotid artery, defined unstable plaque (soft
carotid plaque).
All operations were performed in a standard
fashion under general anesthesia and EEG monitoring
with minimal manipulation of the carotid plaque
specimen. The plaques were obtained and processed
immediately after endarterectomy.
All tissues were stored at 270 8C under liquid
nitrogen after the plaque was divided longitudinally
into four pieces for further analyses. Two blood
samples were also drawn from each patients 24 h
before and after surgery to determine bFGF and MMP
plasma levels. Ten healthy volunteers were enrolled to
measure their bFGF circulating levels. The release,
expression and activity of MMP-2 and MMP-9 were
then evaluated in the carotid plaque specimens.
Thereafter, similar experiments were conducted on
human umbilical artery SMC (HUASMC) culture and
inhibition tests with anti-bFGF antibody were per-
formed to assess the role of this growth factor in
regulating the expression of MMP.
In vivo experiments
Enzyme linked immunosorbant assay (ELISA)
Plasma was obtained from EDTA-anticoagulated
peripheral blood samples centrifuged at 4000g for
10 min. Plasma levels of 72 kDa MMP-2 and 92 kDa
MMP-9 were determined with ELISA technique
(Quantikine humanMMP-2 and -9, R&D Systems
Europe Ltd, UK). Aliquots of diluted plasma (1:50
and 1:20, respectively) from all patients were ana-
lyzed. Similarly, bFGF plasma levels were determined
with ELISA technique (Quantikine humanFGF basic,
R&D).
Zymography
Zymography, able to differentiate between active and
latent enzyme forms, quantified MMP activities. The
carotid plaque specimens were homogenized (Ultra-
Turrax T 25, IKA-Labortechnik), lysed (0.3 g/tissue/
mL) with an ice-cold lysis buffer (50 mM Tris/HCl pH
8.0, 150 mM NaCl, 1% Triton X-100, 0.1% sodium
dodecyl sulfate (SDS), 0.5% sodium deoxycholate,
0.2% sodium azide, 200 mM PMSF, 1 mM Leupeptina,
1 mM Pepstatin A), clarified (16,000g for 30 min), and
the protein concentration determined using Bradford
protein assay (Sigma Chemical Co., St Louis, MO,
USA). Zymography was performed with 1 mg total
protein. The presence of MMP-2 and MMP-9 was
demonstrated using 10% SDS-polyacrylamide gels
containing 1 mg/mL gelatin (Sigma) under non reduc-
ing conditions at constant voltage (120 V) for approxi-
mately 1.5 h. Gels were washed twice (30 min) with
2.5% Triton X-100 (Sigma) on a rotary shaker and
incubated (24 h at 37 8C) in zymographic buffer (0.5 M
Tris/HCl pH 7.5, 50 mM CaCl2, 2 M NaCl, 0.2% Brij
35). Gels were stained using 0.5% Coomassie brilliant
blue R-250. HT-1080 fibrosarcoma cells were used as
positive control. Clear areas on the Coomassie-stained
gel which indicated the presence of proteolitic activity,
were quantified by densitometric scanning. Densito-
metry of destained areas was quantified with the use
of an Imaging Fluor-S (Bio-Rad, Hercules, CA, USA)
densitometer connected to a personal computer. All
results were normalized to the positive control. The
identities of the lytic zones on the zymograms were
confirmed as MMP-2 and MMP-9 (72 kDa for MMP-2
and 92 kDa for MMP-9) by immunoblotting.
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Western blot analysis
The specimens were homogenized (Ultra-Turrax T 25),
lysed with a ice-cold lysis buffer, clarified, and the
proteins concentration was determined. Forty micro-
gram of total protein of tissue extracts were suspended
in reducing buffer. The samples were then separated
by 8% SDS-PAGE for 1.5 h at 120 V and blotted into
nitrocellulose for 1 h at 100 V. The membranes were
incubated in blocking buffer (5% nonfat dry milk, 0.1%
Tween 20, PBS) and probed overnight with the mouse
monoclonal anti-human MMP-2 and -9 (R&D)
(1 mg/mL) IgG antibody. The membranes were incu-
bated with specific secondary horseradish peroxidase-
conjugated anti-mouse antibody (1:2000 dilution)
(Amersham Pharmacia Biotech, Little Chalfont, Buck-
inghamshire, UK) and developed with the use of
chemiluminescence ECL Kit (Amersham), and
exposed to Kodak XAR X-ray film for 1, 5 and
10 min. Human recombinant MMP-2 and -9 (150 ng)
were used as positive controls. Densitometry of the
bands was performed described above.
Reverse transcription polymerase chain reaction (RT-PCR)
The total cellular RNA by the RNAfast method
(Molecular system, San Diego, CA, USA) from the
resulting fine tissue powder was extracted. Reverse
transcription was performed with 1 mg of total RNA
by using, in each sample, 150 pmol of random
hexamers (Boehringer Mannheim, GmbH, Germany),
with 50 units per sample of M-MuLV Reverse
Transcriptase (HT Biotechnology Ltd, Cambridge,
UK) at 42 8C for 1 h, in the manufacturer’s assay
buffer (20 mL final volume) plus 20 units of human
placental ribonuclease inhibitor (HT Biotechnology),
and 200 mM dNTPs, followed by heat inactivation at
94 8C for 5 min. Subsequently, PCR reactions were
performed with specific primers for MMP-2 (accession
number NM_004530; sense: GGATGATGCCTTTGCT-
CGTGC, antisense: CATCGTAGTTGGCTGTGGTCG;
annealing temperature 60 8C; product 729 bp), MMP-9
(accession number AF538844; sense: GTGGCAGA-
GATGCGTGGAGAGTCG, antisense: TTGCCCAGG-
GACCACAACTCGTC; annealing temperature 64 8C;
product 472 bp) and b-actin (accession number
NM001101; sense: GCGAGAAGATGACCCAGAT-
CATGTT, antisense: GCTTCTCCTTAATGTCACG-
CACGAT; annealing temperature 60 8C; product
300 bp) primers as an internal control. In all reactions
10 pmol of each primer and one unit of Super Taq
DNA polymerase (Thermus thermophilus DNA poly-
merase) (HT Biotechnology) were used. PCR was
performed in a final volume of 50 mL in the manufac-
turer’s assay buffer plus 200 mM dNTPs. After an
initial denaturation step of 5 min at 94 8C, the PCR
procedure consisted of scalar cycle number (from 30 to
20) of 1 min. at 94 8C, 1 min at specific annealing
temperature for each primers, 1, 5 min at 72 8C,
followed by 10 min at 72 8C, on a Perkin–Elmer
Cetus Thermal Cycler model 480. Electrophoresis of
15 mL of the PCR reaction was performed under
standard conditions. All gels were photographed
with a Polaroid DS-34 camera using Polaroid 667
films and scanned by a Kodak camera Megaplus
model 1.4. The images were acquired by Imaging
Fluor-S (Bio-Rad) densitometer. The MMP-2, MMP-9
and b-actin expressions were assessed starting, for
each experimental condition, from aliquots of the same
cDNA preparation. The linearity range of the assay
was checked by the method of scalar cycle number.
The results were expressed as the ratio MMP-2/
b-actin and MMP-9/b-actin.
Immunohistochemical analysis
Specimens from carotid plaques were fixed in 10%
neutral buffered formalin and subsequently decalci-
fied in formic acid. The plaques were dehydrated in
graded ethanol and embedded in paraffin. Serial
sections (3 mm thick) were obtained every millimeters
throughout the length of the plaque. The resulting
sections were mounted on APES (DAKO, Glostrup,
Denmark) coated slides. Briefly, tissue sections were
deparaffinized in xylene, rehydrated in graded ethanol
and treated with methanol containing 0.3% H2O2 to
block endogenous peroxidase activity. Slides, in citrate
buffer, were placed in microwave oven for 10 min at
65 8C and then incubated in 10% normal horse serum
(NHS) (Vector Laboratories Ltd, Peterborough,
England) for 30 min at room temperature. NHS was
removed and slides were incubated overnight at 4 8C
with mouse anti-human MMP-2 and -9 (1:100) (R&D).
Slides were then washed twice in PBS and horseradish
peroxidase-conjugated anti-mouse secondary anti-
body (1:200 dilution) were used. Subsequently avidin-
biotin complex (Vector) was added and the peroxidase
reaction was performed using 0.06% diaminobenzi-
dine (Sigma) and 0.01% hydrogen peroxide. After a
final rinse, sections were dehydrated in ethanol,
cleared in xylene and mounted in Permount.
In vitro experiments
Stimulation of MMP-2 and -9 release, activity and
expression by bFGF
To study the effect of bFGF on MMP-2 and MMP-9
release, expression and activity, HUASMC (Clonetics,
Cambrex BioScience Rockland, Inc., USA) were cul-
tured in SmBM (smooth muscle cell basal medium)
bFGF and Metalloproteinases 91
Eur J Vasc Endovasc Surg Vol 28, July 2004
(Clonetics-Cambrex) supplemented with 20% Fetal
Calf serum (FCS). They were grown in an environment
of 5% CO2 at 37 8C. Culture medium was changed
every two days. For stimulation experiments cells at
confluence were stimulated after 24 h of cultivation in
a serum-free medium with 20, 30 and 100 ng/mL of
bFGF (Peprotech EC Ltd, UK). The conditioned
medium was then removed, centrifuged for 5 min at
16,000g and stored at 280 8C. The presence of MMP-2
and -9 was assayed with ELISA technique (Quantikine
humanMMP-2 and -9, R&D).
To determine whether bFGF affected the levels of
proteolytic enzymes, the conditioned medium from
HUASMC exposed to bFGF, was examined for its
gelatinolytic activity by zymography. MMP-2 and -9
protein levels were tested by Western blotting in the
same conditioned medium. To further determine
whether the regulation occurs at the mRNA level,
RT-PCR was performed on mRNA, isolated with the
RNA fast method, fromHUASMC, stimulated for 24 h
at confluence, with bFGF (20, 30 and 100 ng/mL) in a
serum free medium.
Inhibition of MMP-2 and -9 release, activity and expression
by anti-bFGF antibodies
To assess the role of bFGF on the release, activity and
expression of MMP-2 and -9, HUASMC were stimu-
lated with bFGF (20, 30 and 100 ng/mL) and an excess
of monoclonal antibody anti-bFGF (5 mg/mL) (Pepro-
tech) was added for 72 h for ELISA, zymography and
Western blot analysis and for 24 h for RT-PCR analysis.
To exclude nonspecific effect of antibody for bFGF
on MMP-2 and -9, HUASMC were cultured in SmBM
supplemented with 20% FCS. They were grown in an
environment of 5% CO2 at 37 8C. Cells at confluence
were stimulated after 24 h of cultivation in a serum-
free medium with 20, 30 and 100 ng/mL of bFGF
(Peprotech) and an excess both of monoclonal anti-
body anti-bFGF (5 mg/mL) (mouse IgG isotype)
(Peprotech) and monoclonal antibody anti-PDGF
(5 mg/mL) (mouse IgG isotype) (Peprotech) added
for 72 h for ELISA, zymography and Western blot
analysis and for 24 h for RT-PCR analysis.
Statistical analysis
Data were analyzed with a computer software
program (SPSS 12.0 for Windows, Basic and Advanced
Statistics, 1989–2003; SPSS Inc., Chicago, IL, USA). All
results are expressed as median and range (between
brackets) of at least 6–8 different experiments. Mann–
Whitney U test and Kruskal–Wallis one-way analysis
of variance were used to compare means. A p-value
less than 0.05 was considered significant.
Results
Nineteen (48%) carotid plaques were echographically
defined as hard and 21 (53%) as soft.
In vivo experiments
ELISA
The circulatingMMP-2 and -9 levels were higher in the
plasma of patients affected with soft plaques when
compared to those with hard plaques [MMP-2,
soft ¼ 1222 (1190–1252) ng/mL and hard ¼ 748
(656–793) ng/mL—p , 0.0001; MMP-9, soft ¼ 26
(22–29) ng/mL and hard ¼ 18 (15–21) ng/mL—
p , 0.0001].
Healthy volunteers had a significantly lower bFGF
plasma levels when compared to patients with
unstable carotid plaques (p , 0.001) and stable plaques
(p , 0.01) (Table 1). Preoperatively, patients affected
with unstable carotid plaques had higher bFGF
plasma levels when compared to patients with stable
plaques (p , 0.001) (Table 1). Twenty-four hours after
endarterectomy, bFGF levels were similar to healthy
volunteers in both groups (Table 1).
Zymography
Four zones of lysis at 62, 72 (active/latent MMP-2), 83
and 92 kDa (active/latent MMP-9) were identified on
zymography of the carotid specimens. The amount of
active MMP-2 and -9 was significantly higher in
patients affected with unstable plaques when com-
pared to stable plaques [MMP-2, soft ¼ 1.3% (1.2–
1.5%) and hard ¼ 1.2% (1.1–1.4%)—p , 0:0001; MMP-
9, soft ¼ 11% (10–13%) and hard 1.4% (1.2–1.6%)—
p , 0:0001]. The amount of latent MMP-2 and -9 was
significantly higher in the soft plaques when com-
pared to hard plaques [MMP-2, soft ¼ 60% (53–68%)
and hard ¼ 29% (24–33%)—p , 0:0001; MMP-9,
soft ¼ 33% (29–36%) and hard ¼ 16% (10–24%)—
p , 0:0001].
Table 1. bFGF plasma levels
Healthy volunteers ðn ¼ 10Þ
bFGF pg/mL
16, (12–19)
Soft carotid plaques ðn ¼ 21Þ
bFGF pg/mL
Preoperative 34, (28–39)
Postoperative 18, (16–21)
Hard carotid plaques ðn ¼ 19Þ
bFGF pg/mL
Preoperative 20, (17–22)
Postoperative 15, (12–18)
Values are expressed as median and range (between brackets).
P. Sapienza et al.92
Eur J Vasc Endovasc Surg Vol 28, July 2004
Western blot
Immunoblotting confirmed the identities of the lytic
zones on the zymograms as MMP-2 and MMP-9 (72
and 92 kDa, respectively). Protein levels of MMP-2
and -9 were more abundant in the soft than in the hard
plaques [MMP-2, soft ¼ 79% (72–84%) and hard¼
50% (46–54%)—p , 0:0001; MMP-9, soft ¼ 69% (64–
72%) and hard ¼ 48% (44–53%)—p , 0:0001].
RT-PCR
The densitometric analysis of the amplified products
corresponding to the MMP-2 and -9 mRNA (729 bp
and 472 bp, respectively) showed that mRNA
expression was significantly higher in the soft plaques
when compared to the hard plaques [MMP-2,
soft ¼ 1.4 (0.9–2.1) and hard ¼ 0.7 (0.3–1.1)—p ,
0:0001; MMP-9, soft ¼ 0.9 (0.4–1.3) and hard ¼ 0.3
(0.1–0.6)—p , 0:0001].
Immunohistochemistry
Immunostaining for MMP-2 and -9 showed the
presence of MMP within the plaque, revealing intense
staining around the plaque core, especially in the
plaque shoulder and cap of the soft plaques when
compared to hard plaques.
In vitro experiments
ELISA
The increase of bFGF concentration from 20 to
100 ng/mL augmented, in a dose dependent manner,
the release of MMP-2 (p , 0:001; p , 0:001 and p ,
0:001; respectively) and -9 (p , 0:001; p , 0:001 and
p , 0:001; respectively) when compared to controls
(Table 2). The addition of monoclonal anti-bFGF
antibody significantly reduced the release of MMP-2
(p , 0:001; p , 0:001 and p , 0:001; respectively)
and -9 (p , 0:001; p , 0:001 and p , 0:001; respect-
ively) when compared to controls (Table 2).
Zymography
Two zones of lysis at 72 (latent MMP-2) and 92 kDa
(latent MMP-9) were identified. The amount of latent
MMP-2 and MMP-9 significantly augmented in a dose
dependent manner with the increase of bFGF concen-
tration from 20 to 100 ng/mL when compared to
controls [MMP-2: 60% (55–68%) p , 0:001; 67% (59–
71%) p , 0:001 and 74% (68–79%) p , 0:001; respect-
ively; MMP-9: 30% (26–38%) p , 0:05; 40% (35–48%)
p , 0:001 and 45% (37–51%) p , 0:001; respectively]
(Fig. 1). The addition of monoclonal anti-bFGF
antibody significantly decreased the proteolytic
activity of MMP-2 and MMP-9 at all concentrations
when compared to controls [MMP-2: 42% (35–48%)
p , 0:001; 50% (42–59%) p , 0:001 and 46% (41–52%)
p , 0:001; respectively; MMP-9: 20% (13–26%) p ,
0:001; 35% (31–38%) p , 0:001 and 38% (33–44%) p ,
0:001; respectively] (Fig. 1).
Western blot
Protein levels of MMP-2 and MMP-9 significantly
augmented in a dose dependent manner with the
increase of bFGF concentration from 20 to 100 ng/mL
when compared to controls [MMP-2: 49% (44–53%)
p , 0:001; 53% (47–61%) p , 0:001 and 60% (52–67%)
p , 0:001; respectively; MMP-9: 52% (47–60%) p ,
0:001; 66% (59–73%) p , 0:001 and 71% (59–80%) p ,
0:001; respectively] (Fig. 2). The addition of mono-
clonal anti-bFGF antibody significantly decreased the
protein levels of MMP-2 and MMP-9 when compared
to controls (MMP-2: 36% (31–44%) p , 0:001; 39%
(33–46%) p , 0:001 and 60% (55–69%) p , 0:001;
respectively; MMP-9: 42% (32–51%) p , 0:001; 31%
(23–38%) p , 0:001 and 19% (15–27%) p , 0:001;
respectively] (Fig. 2).
RT-PCR
The densitometric analysis of the amplified products
corresponding to the MMP-2 and -9 mRNA (729 bp
and 472 bp, respectively) showed that mRNA
expression significantly increased in a dose dependent
Table 2. Release of MMP-2 and -9 after bFGF stimulation and inhibition
MMP-2
Control 25, (18–28)
Stimulation 20 ng/mL 30 ng/mL 100 ng/mL
40, (36–42) 71, (64–73) 243, (237–258)
Inhibition 20 ng/mL þ 5 mg/mLabFGF 30 ng/mL þ 5 mg/mLabFGF 100 ng/mL þ 5 mg/mLabFGF
20, (17–22) 54, (51–57) 160, (155–167)
MMP-9
Control 5.5, (4.9-6.1)
Stimulation 20 ng/mL 30 ng/mL 100 ng/mL
16, (13–19) 18, (14–21) 20, (16–27)
Inhibition 20 ng/mL þ 5 mg/mLabFGF 30 ng/mL þ 5 mg/mLabFGF 100 ng/mL þ 5 mg/mLabFGF
8, (7–11) 7, (4–9) 8, (5–11)
Values are expressed as median and range (between brackets).
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manner with the increase of bFGF concentration from
20 to 100 ng/mL when compared to controls [MMP-2:
1.4 (1.1–1.6) p , 0:001; 2 (1.6–2.4) p , 0:001 and 2.3
(1.9–2.6) p , 0:001; respectively; MMP-9: 1.9 (1.5–2.2)
p , 0:001; 2.3 (2.1–2.7) p , 0:001 and 3 (2.5–3.4)
p , 0:001; respectively] (Fig. 3). The addition of
monoclonal anti-bFGF antibody to the medium of
HUASMC exposed to bFGF at every concentrations,
significantly decreased the mRNA expression of
MMP-2 and MMP-9 when compared to controls
[MMP-2: 1.2 (0.9–1.4) p , 0:001; 0.3 (0.1–0.5) p ,
0:001 and 1.4 (1.1–1.7) p , 0:001; respectively; MMP-
9: 1 (0.8–1.3) p , 0:001; 0.4 (0.1–0.6) p , 0:001 and 0.5
(0.2–0.9) p , 0:001; respectively] (Fig. 3).
Effect of nonspecific antibody for bFGF
The addition of monoclonal anti-bFGF and anti-PDGF
antibody to the medium of HUASMC exposed to
bFGF at every concentrations from 20 to 100 ng/mL
not significantly decreased the activity, production
and expression of MMP-2 and MMP-9 when com-
pared to controls (p ¼ NS).
Discussion
The atherosclerotic plaque is a dynamic structure that
undergoes continuous remodeling of the extracellular
matrix on which its structural integrity depends. The
matrix degrading MMP promote physiological turn-
over of all extracellular matrix components. Deregu-
lated degradation of basement membrane may lead to
plaque instability and acute plaque changes immedi-
ately precede the onset of clinical symptoms. Each
phase of this process is mediated by a series of MMP,
secreted as latent pro-enzymes which require acti-
vation by limited proteolysis. The events leading up to
this activation remain unclear.
Few studies have examined the interactions
between connective tissue mitogens andMMP, despite
the fact that both are present in atherosclerotic
plaques. Increased levels of connective tissue mitogens
at the site of inflammation have been described and
are able to mediate various biological responses.12,13
The site of plaque rupture is characterized by an
intense inflammatory infiltration,14 which consists
predominantly of macrophages, foam cells, and
T-lymphocytes playing a role in the destabilization of
the plaque.15 This infiltrate undergoes a period of
activation at the time of acute coronary syndromes and
the associated release of proteolytic enzymes may lead
to plaque instability.16
In the present study, we demonstrated that there
was an increased plasmatic concentration of MMP-2
Fig. 1. bFGF effects on MMP-2 and MMP-9 gelatinase activity in HUASMC. 72-kDa MMP-2 and 92-kDa MMP-9 bands were
detected (a). Conditioned medium obtained from HUASMC not exposed to bFGF (lanes 1), exposed to bFGF at
concentrations of 20 ng/ml (lanes 2), 30 ng/ml (lanes 4) and 100 ng/ml (lanes 6) and exposed to bFGF with the addition of
monoclonal anti-bFGF antibody at the same concentrations (lanes 3, 5, 7, respectively). HT1080 cells were used as positive
controls (lanes 8). The ratios between optical density (OD) of MMP and HT1080 are shown in the bar graph (b).
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and -9 in patients affected with unstable carotid
plaques. Recently, Loftus et al.17 have observed that
plasma MMP-9 levels are elevated in patients with
embolizing carotid plaques. The Authors also tested
other MMP but did not found any differences between
stable and unstable carotid plaques. Kai et al.18
demonstrated an early increase in circulating levels
of both MMP-2 and -9 in patients with acute coronary
syndromes. Our findings have also shown that there is
an increase in the gelatinase activity, production and
gene transcription of MMP-2 and -9 in the unstable
plaques. Both active and latent MMP-2 and -9 forms
had a significantly higher gelatinase activity in
unstable plaques when compared to stable plaques.
However, other Authors9 have found a significantly
higher intraplaque level, activity and expression of
MMP-9 but no differences in the level of MMP-2 or
otherMMP in carotid specimens from patients affected
with embolizing plaques.
The plasmatic level of bFGF in patients affected
with soft carotid plaques were higher than in those
with hard plaques and both were higher as compared
to healthy subjects. Interestingly, 24 h after surgery, the
plasma levels of bFGF returned to normal values.
Katinioti et al.19 reported that bFGF circulating levels
were higher in patients affected with coronary artery
diseases as compared to normal subjects. The plas-
matic levels of bFGF returned to normal after coronary
angioplasty and remained stable for 6 months after the
procedure. Since the atherosclerotic process affects
several arterial districts, this phenomenon is not easy
understandable. In our population bFGF serum levels
seem to be related to the presence of carotid artery
stenosis and decrease to normal values after
endarterectomy.
Our study pointed out that the stimulation of
HUASMC with bFGF determined a significant
increase in the release, activity, production and
expression of MMP-2 and -9. This increase was dose-
dependent and the inhibition with monoclonal anti-
bFGF antibodies significantly decreased the release,
activity, production and expression of MMP-2 and -9.
The effect of bFGF on MMP-2 and -9 should be also
viewed under various aspects. bFGF is normally
found in extracellular matrix20,21 because of its strong
interaction with heparin which reflects the affinity for
Fig. 2.Western blotting of MMP-2 and -9. Samples derived fromHUASMC not exposed to bFGF (lanes 1), exposed to bFGF at
concentrations of 20 ng/ml (lanes 2), 30 ng/ml (lanes 4) and 100 ng/ml (lanes 6) and exposed to bFGF with the addition of
monoclonal anti-bFGF antibody at concentrations of 20, 30 and 100 ng/ml (lanes 3, 5 and 7, respectively) (a). The identity of
the bands as MMP-2 and -9 was confirmed with a human recombinant MMP-2 and -9 (150 ng/ml) electrophoresed as a
positive control (lane 8) (a). The ratios between optical density (OD) of MMP and hrMMP-2 and -9 are reported in the bar
graph (b).
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extracellular matrix heparan sulfate proteoglycans
and glycosaminoglycans and it is stored in the
extracellular structures and mobilized when needed
by remodeling of the basement membrane or extra-
cellular matrix.21,22 Furthermore, bFGF is able per se to
suppress collagen synthesis thus contributing to
plaque instability.23
Kenagy et al.24 observed that part of the stimulatory
effect on primate SMC migration caused by bFGF is
mediated byMMP-2 and -9. However, while MMP-2 is
constitutively expressed by vascular SMC and is
physiologically activated by the membrane-bound
MMP, which contains a trans-membrane domain
within the structure, the stimulus for an increased
MMP-9 production, not constitutively expressed, may
depend on activation by several growth factors
simultaneously.
Bond et al.25 have found in fact that MMP-9 is
synergistically upregulated by growth factors and
inflammatory cytokines in rabbit and human fibro-
blasts. Increased expression of MMP-9 occurs in
response to IL-1 and tumor necrosis factor-a in a
number of cell types26,27 and human SMC do not make
MMP-9 constitutively or in response to bFGF.
Conversely, in our study we found that MMP-9
in HUASMC may respond differently to bFGF
stimulation than other type of cells.26 Although we
cannot exclude the interaction with other growth
factors or cytokines normally secreted by HUASMC,
we believe that bFGF may exert a key role in the
upregulation of MMP-9 on HUASMC. Our results are
also consistent with the observation that bFGF seems
to regulateMMP-2. The increase of bFGF in the plasma
of patients affected with carotid artery stenosis which
is even higher in the plasma of patients with unstable
plaques, may lead to the hypothesis that this growth
factor is able to upregulate MMP-2 and -9. Further
studies are required to better understand the under-
lying mechanisms at the basis of this phenomenon.
In conclusion, our results suggest that bFGF plays a
key role in the instability of the carotid plaque
upregulating the expression of MMP-2 and -9 capable
of degrading collagen type IV which is the major
component of the basement membrane.
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